Important things you should know before you give your child with ADHD Medications

 Important Things You Must Know Before Giving Your Child ADHD Medication

hyperactivity disorder

attention deficit known as a psychiatric disorder that causes inattention, hyperactivity, impulsivity or is not appropriate for the age of a person. Did you know that ADD and ADHD are not medical conditions? No brain scan or blood test to diagnose ADHD. However, doctors can make any child on a schedule I or II drug prescription mortal.

line2 line2

important things you should know before you give your child with ADHD Medication

According to Dr. Tasneem Bhatia

“ADD and ADHD are the result of neurotransmitters and neuroendocrine imbalances. the four major imbalances include high norepineprine and cortisol, dysfunction of dopamine, serotonin deficiency, and insulin irregularity. Each one of these imbalances stem from nutritional deficiencies that correction, improves symptoms of hyperactivity and inattention. allergies and food intolerances also contribute to poor absorption of nutrients. ”

Controversy about ADHD has existed since 1970. Discussion topics include concerns about its causes, it is even existence, it suggested treatment, and the use of stimulant drugs as a treatment for children and the criteria used for the diagnosis of ADHD. For a diagnosis of ADHD to be made, symptoms must begin at age 6 to 12 and continued for more than 6 months.

The ADHD Fraud: How Psychiatry makes “Patients” of Normal Children

Other concerns are of a possible overdiagnosis, misdiagnosis as ADHD It is leading to treating other psychiatric disorders. According to the American Journal of Psychiatry, there are concerns regarding increased severity of schizophrenia and bipolar disorder, in patients with a history of stimulant use for ADHD in childhood. Stimulant medications are not approved for children between the ages of 2 and 6 years. Despite this, between 0.51% and 1.23% of children between the ages of theses being treated with stimulants in the US ..

The National Institute of Mental Health states that “under medical supervision, stimulant medications are considered safe,” and therefore, recommend stimulants to treat ADHD. Although the February 9, 2006, the Food and Drug Administration recommended a warning label that recognizes the cardiovascular risks of the use of stimulant drugs to treat ADHD. This seems so terrible because stimulants are classified as Schedule II controlled substances in the United States.

line2 line2

In a recent interview on MSNBC, drug abuse and addiction expert Carl Hart of Columbia University said that “there is not much difference between demonized street drug methamphetamine (also known as meth or crystal meth) and the prescription drug Adderall.”

stimulants to treat ADHD

stimulants that are prescribed include, but are not limited to: Ritalin (methylphenidate) and Adderall (a mixture of amphetamine and dextroamphetamine). Treatment with stimulant drugs are very dangerous.

  • According to scientific research by the FDA and the National Institute of Mental Health, drugs such as Ritalin increase the risk of sudden death by five hundred percent among children and adolescents funded.
  • Ritalin treatment has many side effects: abdominal discomfort, stomach pain, nausea, vomiting, loss of appetite and weight loss. Emotional and behavioral side effects, nervousness, irritability, emotional ups and downs, insomnia and dizziness, headaches, irritability, moodiness, tearfulness, emotional sensitivity, tics or spasms and nervous habits.

Ritalin can be addictive in some patients. The withdrawal of this drug causes several effects :. Fatigue, depression, sleep disorders, malnutrition and cardiovascular complications that can lead to stroke and even death

  • prescription of Adderall have increased from 1.3 million in 1996 to nearly 6 million dollars in 1999. Adderall is a combination of amphetamine and dextroamphetamine. Dextroamphetamine and amphetamine can be habit forming.
  • Side effects, including ::
    nervousness, restlessness, difficulty falling asleep or staying asleep uncontrollable shaking of a body part, headache, changes in sexual ability or desire, dry mouth, stomach pain, nausea, vomiting, diarrhea, constipation, loss of appetite, weight loss.

NIH recommends that anyone experiencing any of these symptoms should call their doctor right away:
fast or pounding heartbeat, dhortness of breath, chest pain, fatigue , slow or difficult, dizziness or fainting, weakness or numbness in an arm or leg, seizures, motor tics or verbal tics, believing things that are not true, feeling unusually suspicious of others, hallucinations (seeing or hearing things that are not there ), mania (frenzied or abnormally excited mood), aggressive or hostile behavior, changes in vision or blurred vision, fever, blistering or peeling skin, rash, hives, itching, swelling of the eyes, face, tongue, or throat, difficulty breathing or swallowing, and hoarseness.

1. Kooij, SJ; Bejerot, S; Blackwell, A; CACI, H; et al. (2010). “European consensus statement on the diagnosis and treatment of adults with ADHD: Adult ADHD European Network”. BMC Psychiatry 10: 67. doi: 10.1186 / 1471-244X-10-67. PMC 2942810. PMID 20815868.

2. Concise Guide to Child and Adolescent Psychiatry (4th illustrated ed.). American Psychiatric Publishing. p. 34. ISBN 9781585624164.

3. “CG72 attention deficit hyperactivity disorder (ADHD): Complete Guide” (PDF). National Health Service in the UK.

4. Ross RG (July 2006). “Psychotic and manic during treatment with stimulants hyperactivity disorder attention deficit symptoms.” The American Journal of Psychiatry 163 (7): 1149-1152. doi: 10.1176 / appi.ajp.163.7.1149 (inactive 04/14/2015). PMID 16816217.

5. “The statistics of stimulant use.” Public Broadcasting Service.

6. Vitiello B (October 2001). “Psychopharmacology for young children: clinical needs and research opportunities.” Pediatrics 108 (4): 983-9. doi: 10.1542 / peds.108.4.983. PMID 11581454.

line2 line2

7. Jim Rosack. “Controversy erupts over ads for ADHD drugs.” Psychiatr News 36 (21): 20-21. doi: 10.1176 / pn.36.21.0020


Source / reference :

You May Also Like: